BRAF and melanoma: However, based on preclinical data that have shown an increase in the levels of both tumour antigens and the expression of major histocompatibility complex (MHC) molecules in patients treated with vemurafenib, combinations of immune checkpoint blockers and BRAF-targeted therapies are currently being tested in melanoma patients.70 This approach will need to be tested in the future for MSI–BRAF-mt mCRC patients.